Gulati G, Tjessem KH, Horndalsveen H, Halvorsen S, Haakensen VD (2022)
[Not Available]
Tidsskr Nor Laegeforen, 142 (18)
DOI 10.4045/tidsskr.21.0817, PubMed 36511752

Horndalsveen H, Alver TN, Dalsgaard AM, Rogg LV, Helbekkmo N, Grønberg BH, Halvorsen TO, Ramberg C, Haakensen VD, Öjlert ÅK, Bjaanaes MM, Helland Å (2022)
Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial
Mol Oncol, 17 (3), 487-498
DOI 10.1002/1878-0261.13330, PubMed 36330681

Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B (2022)
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
J Thorac Oncol, 18 (2), 181-193
DOI 10.1016/j.jtho.2022.10.003, PubMed 36307040